Llenalia Gordillo García

Dr. Llenalia Gordillo García

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2026 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
MFMaría Paloma Flores-Paloma
María Paloma Flores-Paloma
JSJavier Ramírez Santos
Javier Ramírez Santos
LGLlenalia Gordillo García
Llenalia Gordillo García
PLPaula Lopez-Sanchez
Paula Lopez-Sanchez
MSManuel David Sánchez-Martos
Manuel David Sánchez-Martos
FGFrancisco Javier González-Martínez
Francisco Javier González-Martínez
Background: Chronic kidney disease (CKD) is increasingly prevalent, leading to more patients requiring hemodialysis. Medium cut-off (MCO) membranes, such as the ELISIO™ HX dialyzer, may enhance middle-to-large molecule removal and reduce inflammation compared with conventional high-flux membranes. This study evaluated the efficacy and safety of ELISIO™ HX versus a standard high-flux dialyzer (Toraylight NS-21S) in terms of molecular reduction rate and inflammation. Methods: We performed a single-center, prospective, randomized crossover study with 12 hemodialysis patients, each treated with Toraylight NS-21S and ELISIO™ HX over four weeks. Pre- and post-dialysis levels of urea, creatinine, albumin, creatine kinase, phosphorus, parathyroid hormone, C-reactive protein (CRP), procalcitonin, interleukin 6 (IL-6), and β2-microglobulin were measured. Pre–post differences were assessed using dialyzer analysis, period-effect and carryover analysis, and non-inferiority analysis. Results: ELISIO™ HX was non-inferior to Toraylight NS-21S for creatinine, urea, phosphorus, procalcitonin, and β2-microglobulin. No significant serum albumin changes were observed with either dialyzer. Adverse events were infrequent and comparable between the dialyzers. Conclusions: ELISIO™ HX appears non-inferior to Toraylight NS-21S and suggests good safety and tolerability. These findings should be interpreted with caution given the study’s limited power.

30 October 2019
Verified
Book Chapter
Open access
PDF file
MVM.Carmen Vidal-Carou
M.Carmen Vidal-Carou
MPMaría Dolores Del Pino Y Pino
María Dolores Del Pino Y Pino
ÁFÁlvaro Pérez Fernández
Álvaro Pérez Fernández
LGLlenalia Gordillo García
Llenalia Gordillo García
MRMaría José López Ruiz
María José López Ruiz
MRMcarmen Ramirez-Tortosa
Mcarmen Ramirez-Tortosa
We present a 59-year-old patient with type 2 diabetes mellitus and massive nephrotic syndrome (anasarca) and biochemical syndrome. The renal biopsy showed a membranous nephropathy (MN). In the blood analysis the patient presented antibodies against M-type phospholipase A2 receptor (anti-PLA2R) positive at a very high titer. Given the existence of idiopathic membranous nephropathy (IMN), treatment was started with a modified Ponticelli regimen, with no response, requiring periodic ultrafiltration sessions. Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with IMN, even after other treatments have failed. We proposed treatment with rituximab based on published evidence. In IMN, the presence of M-type anti-receptor antibodies of A2 phospholipase is considered highly specific to idiopathic forms, but the presence of such antibodies has not been shown to be associated with a particular clinical profile. Assessing circulating anti-PLA2R autoantibodies and proteinuria may help in monitoring disease activity and guiding personalized rituximab therapy in nephrotic patients with IMN.